Affimed raises $30M in fresh funds; Chimerix wins $17M contract extension; VentiRx gets fast-track status;

@FierceBiotech: Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data. Article | Follow @JohnCFierce

@EmilyMFierce: On-off switch found for natural antibiotics maker. Story | Follow @EmilyMFierce

> Germany's Affimed Therapeutics garnered $15.7 million in an E round, with Aeris Capital BioMedInvest LSP Life Sciences Partners Novo Nordisk A/S and Orbimed all chipping in. Also, the company lined up a $14 million loan from Perceptive Advisors. Release

> Durham, NC-based Chimerix has won a $17 million contract extension from BARDA to develop brincidofovir as a remedy for smallpox. Release

> The 2010 Fierce 15 winner VentiRx has won fast-track status for its ovarian cancer drug, according to CEO Robert Hershberg. Hershberg was recently named head of early development in immuno-oncology by Celgene and plans to take a reduced role at the biotech. Story

> Galleon Pharmaceuticals said it garnered "clinically and statistically significant results" from a proof-of-concept study of its lead investigational drug GAL-021 in normal volunteers. Release

Medical Device News

@FierceMedDev: ICYMI: looks to sell off Cordis for as much as $2B. Article | Follow @FierceMedDev

@VarunSaxena2: Attorney: Latest UDI guidance unhelpful, many questions left unanswered. Story | Follow @VarunSaxena2

@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. FierceDrugDelivery story | Follow @MichaelGFierce

> Boston Scientific faces stinging setback for vagus nerve stimulation device in mid-stage trial. Story

> Dime-sized device can separate healthy and cancerous cells. Article

> Can the nose bone be connected to the knee bone? More

Pharma News

@FiercePharma: ICYMI: Are specialty pharma CEOs worth their salt? Story | Follow @FiercePharma

@EricPFierce: Pablo Manuel Fernandez is on the the FDA Most Wanted list. He sold $12M worth of counterfeit Viagra. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Are specialty pharma CEOs worth their salt? More | Follow @CarlyHFierce

> Novartis ready to start its engines for 'most exciting launch' in company history. Item

> Cipla's Advair copy gathers steam with rollouts in Germany, Sweden. More

> Key Adcock stakeholder defends thwarted CFR merger. Article

CRO News

> Synexus snags another South African site and widens its footprint. Report

> Cenix lands an early-phase deal with BASF's Metanomics. News

> CRO Onyx signs up to help CRUK handle cancer R&D. More

> PRA sets sights on a new HQ. Story

> Catalent lends its weight to an armed-antibody cancer candidate. Article

Biotech IT News

> J&J, Sanofi apply IBM's Watson to R&D. News

> Takeda strikes deal with C4X to access 3D drug structure tech. Article

> Apple tightens health data privacy rules ahead of HealthKit launch. More

> Hackers target pharma's 'golden nuggets' to steal a lead in R&D. Story

> Amazon's meeting with FDA starts the rumor mill turning. Item

Animal Health News

> Boehringer to stay focused on porcine type 2 vaccine; dropping its RTU program. News

> Survey: Midwest corridor is a global magnet for animal health companies. Report

> Could a pair of offerings be the first signs of animal health IPO momentum? Article

> Mars Petcare issues four-state recall for 22 bags of Pedigree dog food. Story

> New Zealand's Simcro to set up North American HQ in Kansas. More

Biotech Research News

> Japanese institute to cut back stem cell research in wake of scandal. More

> Japanese institute to cut back stem cell research in wake of scandal. Report

> Gene therapy prevents botulism in mice. Article

> ZMapp antibody therapy prevents Ebola infection in monkeys. Item

> Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. Story

Pharma Manufacturing News

> Indian drugmakers giving up 'advantage' to move to higher-margin drugs. More

> Adcock shareholder on defense for opposing buyout by CFR. News

> Could a pair of offerings be the first signs of animal health IPO momentum? More

> Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant. Story

> Sources: West Pharmaceutical looks at $130M investment in Ireland. Article

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.